Atriva Therapeutics is a clinical stage biopharmaceutical company developing host-targeting inhibitors against severe respiratory viral infections.

Adresse: Mergenthaler Allee 10-12 | 65760 Eschborn | Germany
Telefon : +49 711/1645-6

Indication:Influenza and other severe respiratory viral infections.
Year founded: 2015
Number of employees: 13
Financing/Partnering: Venture round EUR 35 Mn: EUR 16 Mn fresh funds to be used for PoC milestone in 2021, plus EUR 19 Mn for Ph IIb milestone in early 2023.

Business Concept
Atriva Therapeutics is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies against different severe respiratory viral infections. The Company, located in Tübingen and Frankfurt, Germany, was founded in 2015 by a team of leading scientists in viral research and seasoned industry experts. Atriva’s lead drug candidate ATR-002 is a host-targeting MEK inhibitor, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development and has successfully proven safety and tolerability in healthy subjects in a Phase I trial. The Company owns nine patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies.

New antiviral mode of action with high resistance barrier and broad activity.

Market Potential:
Over EUR 700 Mn projected retail peak sales of ATRIVA’s MEK inhibitors in Influenza to be reached five years after first launch.

ATR-002 has successfully proven safety and tolerability in healthy subjects in a Phase I trial.

Ihre Ansprechpartner

Dr. Rainer Lichtenberger

Folgen Sie uns in den Sozialen Medien

    Schweizer Medienkonzern investiert in Blockchain-Technologie
    Mehr Infos und Hintergründe in unserem kostenfreien Newsletter

    Jetzt abonnieren